8-K: Tivic Health Announces Positive Results from Non-Invasive Vagus Nerve Stimulation Pilot Study

Tivic Health's pilot study demonstrates significant biological changes using non-invasive vagus nerve stimulation, showing potential for clinical applications.

Summary

• Tivic Health has announced the final results of a pilot study conducted with The Feinstein Institutes for Medical Research at Northwell Health.
• The study evaluated the effects of Tivic Health's non-invasive cervical vagus nerve stimulation (ncVNS) on the autonomic nervous system, cardiac function, and brain activity in twenty healthy subjects.
• The ncVNS intervention was administered for twenty minutes to each participant.
• The study showed a 97% increase in the root mean square of successive differences (RMSSD), a measure of heart rate variability and a proxy for vagus nerve activity.
• EEG measurements showed a 24% increase in frontal theta power and a 66% reduction in frontal gamma power, indicating reduced arousal and anxiety.
• Subjects experienced a 9.5% reduction in pupil diameter during stimulation, which is associated with parasympathetic nervous system activation.
• The company believes these results suggest potential clinical utility in various patient populations, including those with epilepsy, post-traumatic stress disorder, and ischemic stroke.

Sentiment

Score: 8

Explanation: The document presents very positive results from a pilot study, with strong indications of clinical potential. The company's management is optimistic, and the results are presented as a significant advancement in the field. However, there are standard forward-looking statements and risk disclosures.

Positives

• The study provides strong validation of Tivic Health's novel approach to non-invasive vagus nerve stimulation.
• The results suggest potential clinical utility in several patient populations, including those with epilepsy, post-traumatic stress disorder, and ischemic stroke.
• The company is encouraged by the magnitude of the treatment effects, particularly in the context of current state of the art.
• The study results will help guide the design of new products leveraging ncVNS.
• The company is energized about these results and looks forward to unlocking valuable new market segments.

Risks

• The forward-looking statements are subject to substantial risks and uncertainties.
• Actual results could differ materially from those contained in any forward-looking statement due to various factors.
• These factors include the future development of ncVNS treatment, the ability to commercialize products, and the plans to seek regulatory approval.
• Other risks include market conditions, supply chain constraints, macroeconomic factors, and unexpected costs.

Future Outlook

Tivic Health plans to use the study results to guide the design of new products leveraging ncVNS and aims to unlock valuable new market segments. The company is also focused on developing ncVNS treatment for conditions like epilepsy, post-traumatic stress disorder, and ischemic stroke.

Management Comments

• Blake Gurfein, Ph.D., Chief Scientific Officer of Tivic Health, stated that they are strongly encouraged by the magnitude of the treatment effects from their ncVNS approach.
• Jennifer Ernst, CEO of Tivic Health, added that their mission is to improve vibrancy of life through advancement of bioelectronic medicine and they are energized about these results.

Industry Context

The announcement is relevant to the growing field of bioelectronic medicine and the neurostimulation market, which is experiencing significant growth. The company is positioning itself as a leader in non-invasive VNS technology, which is a growing area of interest in the medical industry.

Comparison to Industry Standards

• Previous studies of non-invasive VNS devices have reported mixed results regarding autonomic nervous system changes, whereas Tivic Health's study showed a 97% increase in RMSSD, a widely accepted proxy for vagus nerve activity.
• The magnitude of the ncVNS data implies potential for greater clinical effects and enhanced reproducibility compared to other non-invasive VNS devices.
• The company is aiming to improve on existing VNS devices, many of which rely on surgical implants, by developing non-invasive or minimally invasive devices.

Stakeholder Impact

• Shareholders may view the positive study results as a positive development for the company's future prospects.
• Patients may benefit from the development of new non-invasive treatment options for various conditions.
• The company's employees may be motivated by the positive results and the potential for growth.
• The company's collaborators, such as The Feinstein Institute, may benefit from the successful study results.

Next Steps

• Tivic Health plans to use the study results to guide the design of new products leveraging ncVNS.
• The company will continue to focus on developing ncVNS treatment for conditions like epilepsy, post-traumatic stress disorder, and ischemic stroke.
• Tivic Health aims to unlock valuable new market segments with this program.

Key Dates

Keywords

vagus nerve stimulation, bioelectronic medicine, non-invasive, neuromodulation, autonomic nervous system, cardiac function, brain activity, epilepsy, PTSD, ischemic stroke